Finance

Lists
Why is 003000 up 5.98%?
Dive Deeper
003000:KRX
Bukwang Pharm Co Ltd
ā‚©3,900.00
+5.98%
(+220.00) 1D
Oct 16, 3:30:30 PM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 003000...
Open
ā‚©3,685
High
ā‚©3,970
Low
ā‚©3,685
Mkt. cap
384.79B
Avg. vol.
563.44K
Volume
337.12K
Dividend
3.21%
Quarterly dividend
ā‚©31
Ex-dividend date
Dec 29, 2025
P/E ratio
42.22
52-wk high
ā‚©9,890
52-wk low
ā‚©3,510
EPS
ā‚©92
Shares outstanding
98.66M
No. of employees
630
Open
ā‚©3,685
High
ā‚©3,970
Low
ā‚©3,685
Mkt. cap
384.79B
Avg. vol.
563.44K
Volume
337.12K
Dividend
3.21%
Quarterly dividend
ā‚©31
Ex-dividend date
Dec 29, 2025
P/E ratio
42.22
52-wk high
ā‚©9,890
52-wk low
ā‚©3,510
EPS
ā‚©92
Shares outstanding
98.66M
No. of employees
630
News stories
From web sources and news partners
About Bukwang Pharm Co Ltd
CEOKim Sang-hun | Hui Won Yoo
Employees630
Founded1960
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in KRW
Loading Previous Earnings...
Revenue
Net income
All values in KRW
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
47.81B
62.51B
47.78B
56.99B
Cost of goods sold
28.36B
29.86B
28.91B
32.59B
Cost of revenue
28.36B
29.86B
28.91B
32.59B
Research and development expenses
4.24B
6.31B
4.56B
7.08B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
14.23B
17.02B
11.50B
15.91B
Operating expense
18.47B
24.50B
17.76B
22.99B
Total operating expenses
46.84B
54.36B
46.67B
55.58B
Operating income
979.05M
8.16B
1.10B
1.41B
Other non operating income
244.96M
3.01B
981.71M
449.24M
EBT including unusual items
1.22B
2.99B
2.09B
1.84B
EBT excluding unusual items
1.22B
11.56B
2.09B
1.84B
Income tax expense
-272.07M
-1.67B
924.48M
447.55M
Effective tax rate
-22.24%
-55.87%
44.32%
24.37%
Other operating expenses
-
628.87M
546.78M
-
Net income
1.53B
4.67B
1.18B
1.40B
Net profit margin
3.20%
7.47%
2.46%
2.46%
Earnings per share
-
-
-
-
Interest and investment income
-
4.71B
-
-
Interest expense
-
-3.90B
-
-
Net interest expenses
-
815.55M
-
-
Depreciation and amortization charges
-
350.64M
642.06M
-
EBITDA
2.40B
9.70B
2.48B
2.48B
Gain or loss from assets sale
-299.00K
-12.46M
-
-49.19M
AI content may include mistakes. Learn more
Google apps